(Q38868199)

English

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?

scientific article published on September 28, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? (English)

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

1 reference

based on heuristic

inferred from title

neoadjuvant therapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21955806

13 December 2024

perioperative care

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21955806

13 December 2024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21955806

13 December 2024

Hassan Errihani

14

object named as

Hassan Errihani

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

author name string

Yassir Sbitti

1

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Ismail Essaidi

2

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Adil Debbagh

3

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Habiba Kadiri

4

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Mohamed Oukabli

5

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Yassine Moussaid

6

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Khaoula Slimani

7

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Mohamed Fetohi

8

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Hakim Elkaoui

9

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Abderrahmane Albouzidi

10

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Mohamed Mahi

11

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Abdelmounaim Ait Ali

12

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Mohamed Ichou

13

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21955806

13 December 2024

publication date

28 September 2011

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

full work available at URL

https://wjso.biomedcentral.com/counter/pdf/10.1186/1477-7819-9-112

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21955806

13 December 2024

https://europepmc.org/articles/PMC3204255

HyperText Markup Language

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21955806

13 December 2024

https://europepmc.org/articles/PMC3204255?pdf=render

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21955806

13 December 2024

http://link.springer.com/content/pdf/10.1186/1477-7819-9-112.pdf

1 reference

10.1186/1477-7819-9-112

https://api.crossref.org/works/10.1186/1477-7819-9-112

13 December 2024

http://link.springer.com/article/10.1186/1477-7819-9-112/fulltext.html

HyperText Markup Language

1 reference

10.1186/1477-7819-9-112

https://api.crossref.org/works/10.1186/1477-7819-9-112

13 December 2024

World Journal of Surgical Oncology

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

112

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

copyright license

Creative Commons Attribution 2.0 Generic

28 September 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Trastuzumab for gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Advances in the treatment of patients with gastric adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

9 September 2017

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

14 September 2017

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Targeted HER2 treatment in advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204255

22 August 2018

Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21955806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1477-7819-9-112

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38868199&oldid=2286763370"